ONC Stock Analysis: Buy, Sell, or Hold?
ONC - BeOne Medicines Ltd. American Depositary Shares
$297.65
6.91 (2.38%)
▲
5d:
+8.1%
30d:
+8.36%
90d:
-3.5%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When ONC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ONC shows positive signals but monitor for confirmation. Market pricing in 7.1% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ONC shows positive signals but monitor for confirmation. Market pricing in 7.1% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$472.88
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$293.62
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ONC is currently trading at $297.65, which is considered extended relative to its 30-day fair value range of $266.15 to $289.42. From a valuation perspective, the stock is trading at a discount (Forward PE: 30.6) compared to its historical average (38.2). Remarkably, the market is currently pricing in an annual earnings decline of 7.1% over the next few years. This pessimistic expectation contrasts with the company's recent 16970.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ONC is in a downtrend. The price is approaching resistance at $300.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ONC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $412.38 (+38.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ONC is in a downtrend. The price is approaching resistance at $300.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ONC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $412.38 (+38.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$266.15 -
$289.42
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 38.5% below Wall St target ($412.38)
Trading Range Analysis
30-Day Trading Range
$266.15 -
$289.42
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$265.02
Resistance Level
$300.19
Current Trend
Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
30.64
Wall Street Target
$412.38
(+38.5%)
Revenue Growth (YoY)
35.5%
Earnings Growth (YoY)
16970.8%
Profit Margin
8.9%
Valuation Discount vs History
-7.1% cheaper
PE vs Historical
30.6 vs 38.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.1%
(market-implied from PE analysis)
1-Year Target
$276.52
(-7%)
2-Year Target
$256.88
(-14%)
3-Year Target
$238.65
(-20%)
3-Yr Target (if PE normalizes)
(PE: 31→38)
$297.49
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 30.6, Growth: 49.2%)
$988.24
(+232%)
Base:
(SPY PE: 21.8, Growth: 49.2%)
$702.40
(+136%)
Bear:
(PE: 18.5, Growth: 49.2%)
$597.04
(+101%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (44x PE), but valuation improves significantly next year (31x PE) as earnings recover.
Forward PE: 44.05 | Forward EPS (Implied): $6.76
Bull Case
$359.41
(+21%)
Analyst growth 15.0%, PE expands to 46.3
Base Case
$297.65
(0%)
Market implied 0.0%, PE stable at 44.1
Bear Case
$227.70
(-24%)
Severe decline -15.0%, PE contracts to 39.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 30.6 to 38.2
Stabilization Target:
$371.05
(+24.7%)
PE Expansion Potential:
+24.7%
Share & Embed Analysis
Last updated: July 03, 2026 4:35 PM ET
Data refreshes hourly during market hours. Next update: 5:35 PM
Data refreshes hourly during market hours. Next update: 5:35 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ONC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Chan Henry Lee
SELL
332 shares
2026-04-08
Chan Henry Lee
SELL
341 shares
2026-03-11
Chan Henry Lee
SELL
1660 shares
2026-02-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 64 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 62 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 58 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 57 HOLD |